Nordea Investment Management AB Has $243.04 Million Stock Holdings in Labcorp Holdings Inc. $LH

Nordea Investment Management AB decreased its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 36.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 967,679 shares of the medical research company’s stock after selling 553,253 shares during the quarter. Nordea Investment Management AB owned approximately 1.17% of Labcorp worth $243,042,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. HBK Sorce Advisory LLC lifted its stake in shares of Labcorp by 4.3% in the 3rd quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock valued at $254,000 after purchasing an additional 38 shares during the last quarter. Pure Financial Advisors LLC increased its position in Labcorp by 3.9% during the third quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock worth $292,000 after buying an additional 38 shares during the last quarter. Hantz Financial Services Inc. increased its position in Labcorp by 48.8% during the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after buying an additional 40 shares during the last quarter. Burney Co. raised its holdings in Labcorp by 0.5% during the third quarter. Burney Co. now owns 8,819 shares of the medical research company’s stock valued at $2,532,000 after buying an additional 42 shares in the last quarter. Finally, Advisor OS LLC raised its holdings in Labcorp by 5.4% during the third quarter. Advisor OS LLC now owns 821 shares of the medical research company’s stock valued at $236,000 after buying an additional 42 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Activity at Labcorp

In related news, CEO Adam H. Schechter sold 8,705 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the completion of the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at $22,613,209.08. This represents a 9.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the sale, the executive vice president directly owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. This trade represents a 17.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,113 shares of company stock valued at $4,547,450 in the last 90 days. 0.84% of the stock is owned by company insiders.

Labcorp Price Performance

Shares of NYSE:LH opened at $263.18 on Monday. The business has a 50 day moving average price of $273.72 and a 200 day moving average price of $269.51. Labcorp Holdings Inc. has a twelve month low of $209.38 and a twelve month high of $293.72. The company has a market cap of $21.69 billion, a price-to-earnings ratio of 25.16, a PEG ratio of 1.80 and a beta of 1.01. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The company had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. During the same period in the previous year, the business posted $3.45 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Research analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Friday, February 27th were given a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. Labcorp’s payout ratio is 27.53%.

Analysts Set New Price Targets

LH has been the subject of several recent analyst reports. Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. JPMorgan Chase & Co. upped their target price on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Piper Sandler boosted their price objective on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $304.82.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.